Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies

References

• Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-CoV-2 delta and omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nature Med. 2022;28(3):481–485. doi: 10.1038/s41591-022-01705-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. Summary status of COVID-19 vaccines within WHO EUL-PQ evaluation process. 2024 Jan 25. https://www.american-club.com/files/files/WHO_COVID-19_EUL_23-March-2021.pdf
   Google Scholar
• World Health Organization. WHO roadmap on uses of COVID-19 vaccines in the context of omicron and high population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, irst issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, updated: 21 January 2022, updated: 30 March 2023, latest update: 10 November 2023[M]//WHO roadmap on uses of COVID-19 vaccines in the context of omicron and high population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, updated: 21 January 2022, updated: 30 March 2023, latest update: 10 November 2023. 2023.
   Google Scholar
• Luvira V, Pitisuttithum P. Effect of homologous or heterologous vaccine booster over two initial doses of inactivated COVID-19 vaccine. Expert Rev Vaccines. 2024;23(1):283–293. doi: 10.1080/14760584.2024.2320861. just-accepted.
   PubMed Web of Science ®Google Scholar
• Zuo F, Abolhassani H, Du L, et al. Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 omicron variant. Nat Commun. 2022;13(1):2670. doi: 10.1038/s41467-022-30340-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO SAGE roadmap on uses of COVID-19 vaccines in the context of OMICRON and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022. 2023 Mar 30.
   Google Scholar
• Zhang L, Cao L, Gao XS, et al. A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2. Natl Sci Rev. 2021;8(8):nwab053. doi: 10.1093/nsr/nwab053
   PubMed Web of Science ®Google Scholar
• Yu J, Yao W, Hu Y, et al. A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques. bioRxiv. 2021-11
   Google Scholar
• Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N Engl J Med. 2021;385(19):1761–1773. doi: 10.1056/NEJMoa2110345
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Barbara L, Miriam S. Safety platform for emergency vaccines-D2.3 priority list of adverse events of special interest: COVID-19. 2020. https://www.bing.com/ck/a?!&&p=5e2cd235b068b450JmltdHM9MTcxMTMyNDgwMCZpZ3VpZD0xNGExOTM5Yy1lOTQzLTY3ZDAtM2ZkZC04NzhmZTgyNTY2YWQmaW5zaWQ9NTE5MA&ptn=3&ver=2&hsh=3&fclid=14a1939c-e943-67d0-3fdd-878fe82566ad&psq=SPEAC+D2.3&u=a1aHR0cHM6Ly96ZW5vZG8ub3JnL3JlY29yZHMvNjY5NzI5Mi9maWxlcy9TUEVBQ19EMi4xX1YyLjBfQ09WSUQtMTlfMjAyMDA1MjVfcHVibGljLnBkZg&ntb=1
   Google Scholar
• China National Medical Product Administration. Guidelines for adverse event classification standards for clinical trials of preventive vaccines. 2019. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20191231111901460.html
   Google Scholar
• Deng J, Ma Y, Liu Q, et al. Comparison of the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(17):10752. doi: 10.3390/ijerph191710752
   PubMed Web of Science ®Google Scholar
• Roa CC Jr, de Los Reyes MRA, Plennevaux E, et al. Superior boosting of neutralizing titers against omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs. A homologous booster in CoronaVac-primed adults. J Infect Dis. 2023;228(9):1253–1262. doi: 10.1093/infdis/jiad262
   PubMed Web of Science ®Google Scholar
• Zhao X, Zhang R, Qiao S, et al. Omicron SARS-CoV-2 neutralization from inactivated and ZF2001 vaccines. N Engl J Med. 2022;387(3):277–280. doi: 10.1056/NEJMc2206900
   PubMed Web of Science ®Google Scholar
• Kaabi NA, Yang YK, Liang Y, et al. Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 omicron and other circulating variants. medRxiv. 2022;2022.09. 05.22279589.
   Google Scholar
• Cheng SM, Mok CKP, Leung YW, et al. Neutralizing antibodies against the SARS-CoV-2 omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nature Med. 2022;28(3):486–489. doi: 10.1038/s41591-022-01704-7
   PubMed Web of Science ®Google Scholar
• Wan EYF, Mok AHY, Yan VKC, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. J Travel Med. 2022;29(8):1–12. doi: 10.1093/jtm/taac119
   Web of Science ®Google Scholar
• Ranzani OT, Hitchings MD, de Melo RL, et al. Effectiveness of an inactivated COVID-19 vaccine with homologous and heterologous boosters against omicron in Brazil. Nat Commun. 2022;13(1):5536. doi: 10.1038/s41467-022-33169-0
   PubMed Web of Science ®Google Scholar
• Chi WY, Li YD, Huang HC, et al. COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J Biomed Sci. 2022;29(1):1–27. doi: 10.1186/s12929-022-00853-8
   PubMed Web of Science ®Google Scholar
• Zou J, Kurhade C, Patel S, et al. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388(9):854–857. doi: 10.1056/NEJMc2214916
   PubMed Web of Science ®Google Scholar
• Link-Gelles R, Ciesla AA, Roper LE, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to omicron BA.5 and XBB/XBB.1.5 related sublineages among immunocompetent adults – increasing community access to testing program, US, Dec 2022 – Jan 2023. Morbidity Mortality Weekly Rep. 2023;72(5):119.
   PubMed Web of Science ®Google Scholar
• Carabelli AM, Peacock TP, Thorne LG, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature Rev Microbiol. 2023;21(3):162–177. doi: 10.1038/s41579-022-00841-7
   PubMed Web of Science ®Google Scholar
• Tregoning JS, Flight KE, Higham SL, et al. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–636. doi: 10.1038/s41577-021-00592-1
   PubMed Web of Science ®Google Scholar